Cooper Companies, Inc. (COO)

Health Care · Health Care Supplies · US stock · S&P 500 component

$61.21 ▼ -0.44 (0.71%)

At close 23 Oct 2026 · USD · Volume 1,816,642

Compare with WST

Interactive chart Research report Forecast ranges Pro workspace SEC filings Historical data

Fair valueFair

$66 +8.5% to fair value

$33fair band $57–$80$100

Day's range

$60.46 – $61.74

52-week range

$51.01 – $89.83

About Cooper Companies, Inc.

Cooper Companies develops and manufactures medical devices through two businesses. CooperVision makes soft contact lenses, which it supplies to eye care professionals and retailers around the world, while CooperSurgical focuses on products for women's health, fertility and newborn care used by hospitals, clinics and fertility specialists.

Revenue comes from the recurring supply of contact lenses and from surgical, diagnostic and fertility products. In the last twelve months it was $4.2 billion, growing at 7.3% a year across the last three years. The operating margin is 12.8%, and the business earns a profit of 4% on the capital invested in it. It has net debt of 3.2 times EBITDA. The company does not pay a dividend. On the site's X-Ray Score it receives 46 out of 100.

Price chart

Interactive chart Historical data & CSV

52-wk range $51.01 – $89.83Volume 1,816,642Daily, split-adjusted

Vitals

Market cap$11.8B

52-week range$51.01 – $89.83

Volume (last day)1,816,642

P/E (TTM)21.1

EBIT / EV yield3.7%

Free-cash-flow yield5.7%

Dividend yieldNo dividend

Revenue (TTM)$4.2B

Net income (TTM)$570M

Operating margin12.8%

Return on capital4.3%

Debt incl. leases$3.2B

Cash & securities$155M

Debt = borrowings plus lease liabilities. Cash & securities = cash, equivalents and short-term marketable securities (long-term securities are not counted, so net cash can be understated for companies that hold large long-term investments). Net debt = debt minus cash & securities. Source: latest SEC 10-Q/10-K. EBIT / EV yield = operating profit divided by market cap plus net debt.

Fair value estimate

$66middle half of models $68 – $74

Fair +8.5% to fair value

Average of the 13 valuation models that pass our checks: multiples, discounted cash flow, dividend discount and earnings power value. A model more than 100% above or 60% below the price is left out as unrealistic. Model uncertainty is High, based on how far apart the models are. Undervalued or Overvalued means the gap to fair value is more than 17.5%.

Price $61

Undervalued < $57Fair $57 – $80Overvalued > $80

P/E multiple

$74

P/B multiple

$95

P/S multiple

$85

EV/EBITDA multiple

$68

EV/EBIT multiple

$73

EV/revenue multiple

$78

10-year DCF, EBITDA exit

$68

5-year DCF, EBITDA exit

$70

10-year DCF, revenue exit

$70

5-year DCF, revenue exit

$73

10-year DCF, growth exit

$34

5-year DCF, growth exit

$30

Earnings power value

$45

Growth the price implies

20.8%/yr

A model estimate, not a price target or recommendation. Inputs: risk-free 4.96%, equity risk premium 4.30% (Damodaran). How it works.

What this means

Weak business, fairly priced

The price sits inside our fair-value band. A high score does not guarantee a good outcome; it shifts the odds a little. Use the checklist as a prompt for your own research.

Before you invest · decision checklist

I understand how this company makes money Business quality is average or better 40 The price is not above fair value $66 fair value Debt looks manageable 3.2× EBITDA Revenue has been growing 7.3% a year Profits are backed by cash There are no red flags none raised I know what share of my savings this would be

Ticked boxes are filled in from our data; the rest are yours to answer.

The five-lens scan

Every score explained in one sentence, ranked against Health Care peers. Open a lens to see the numbers behind it.

Strong: 70 to 100Fair: 50 to 69Weak: under 50No score: not enough data

Valuation Fair

58/100

Priced about in line with its sector.

See the numbers →

EBIT / EV yield3.7%

Free-cash-flow yield5.7%

Fair value vs price1.1×

Growth Weak

46/100

Growing slower than most of its sector.

See the numbers →

Revenue growth (3y)7.3%

EPS growth (3y)-1.2%

Growth consistency100%

Profitability Weak

37/100

Earns lower returns on its capital than most peers.

See the numbers →

Return on invested capital4.3%

Operating margin12.8%

Gross profitability22.0%

Financial health Weak

42/100

Balance sheet is more stretched than most peers.

See the numbers →

Piotroski F-Score6 / 9

Net debt / EBITDA3.2×

Interest cover6.1×

Dividends None

–/100

Pays no dividend.

See the numbers →

Quarterly results: last 6 quarters

+6.3%

Apr '25

+5.7%

Jul '25

+4.6%

Oct '25

+6.2%

Jan '26

+7.9%

Apr '26

+0.6%

Jul '26

Revenue against the same quarter a year earlier. Latest quarter revenue $1.1B, diluted EPS $2.24.

Compare with peers

ALGN Align Technology Inc61 WST West Pharmaceutical Se...45

Other Health Care Supplies companies by X-Ray Score.

SWOT analysis: Cooper Companies, Inc.

Strengthsinside the company

Free cash flow equals 5.7% of the market value, which funds dividends, buybacks or debt paydown.

Weaknessesinside the company

Return on invested capital is only 4.3% (median 12.5% for sector peers), so the business earns little above its cost of capital.

Opportunitiesvaluation and setting

Trades at 20.8x earnings, 27% below the 28.5x median of sector peers.

Threatsvaluation and setting

Valuation uncertainty is high: the models give widely different values, so the fair value range is wide.

Written by fixed rules from the figures on this page and the peer table below: filings, our fair value, the sector climate and the price trend. It summarises the data, it is not a forecast or advice.

Compare COO with peers and sector

Medians of 59 Health Care peers and of 59 Health Care stocks in our universe. Largest peers (X-Ray Score): LLY 61, JNJ 49, ABBV 41, UNH 58, MRK 33, TMO 34.

Metric	COO	Peers	Sector
X-Ray Score (out of 100)	46	49	49
Valuation	58	53	53
Growth	46	48	48
Profitability	37	51	51
Financial health	42	48	48
Dividends	–	51	51

Sector leaders: highest X-Ray Score in Health Care

COO ranks #38 of 60 in Health Care by X-Ray Score. A higher score is stronger on our five pillars; it is a ranking of facts, not a forecast.

Company	X-Ray Score
#1 INCY Incyte Corp	80
#2 DXCM Dexcom Inc	78
#3 PODD Insulet Corp	72
#4 RMD Resmed Inc	70
#5 ZTS Zoetis Inc.	69
…
#38 COO Cooper Companies, Inc. (this stock)	46

Metric	COO	Peers	Sector
P/E ratio	20.8x	28.5x	28.5x
PEG ratio	–	2.29	2.29
Price / book	1.4x	3.9x	3.9x
Price / sales	2.8x	3.7x	3.7x
EV / EBITDA	16.0x	17.7x	17.7x
Price / free cash flow	17.5x	22.4x	22.4x
Dividend yield	–	1.0%	1.0%
Gap to our fair value	+8.5%	−0.7%	−0.7%

Metric	COO	Peers	Sector
Price change, 1 month	+9.2%	+7.7%	+7.7%
Price change, 3 months	−12.8%	+10.7%	+10.7%
Price change, 6 months	−5.8%	+21.2%	+21.2%
Price change, 1 year	−17.9%	+19.1%	+19.1%

Metric	COO	Peers	Sector
Market value	$11.8B	$50.9B	$50.9B
Revenue (last 12 months)	$4.2B	$14.7B	$14.7B
EBITDA (last 12 months)	$928M	$2.7B	$2.7B
Net income (last 12 months)	$570M	$1.4B	$1.4B
Free cash flow (last 12 months)	$678M	$2.3B	$2.3B

Metric	COO	Peers	Sector
Revenue growth, last year	+5.1%	+7.2%	+7.2%
Revenue growth, 3 years a year	+7.3%	+5.5%	+5.5%
EPS growth, 3 years a year	−1.2%	+5.5%	+5.5%
Free cash flow growth, 3 years a year	−1.3%	+4.5%	+4.5%
Dividend growth	–	+4.2%	+4.2%

Metric	COO	Peers	Sector
Gross margin	65.9%	65.0%	65.0%
EBITDA margin	21.9%	20.5%	20.5%
Operating margin	12.8%	16.9%	16.9%
Net margin	13.5%	10.0%	10.0%
Return on invested capital	4.3%	12.5%	12.5%
Return on equity	6.8%	13.7%	13.7%

Metric	COO	Peers	Sector
Net debt / EBITDA	3.2x	2.0x	2.0x
Interest cover	6.1x	10.4x	10.4x
Current ratio	1.2x	1.5x	1.5x
Piotroski F-score (0 to 9)	6	6	6

Green means better than the peer median, red worse (only where a higher or lower figure is clearly better). A dash means too few companies report the figure. P/E, EV/EBITDA and price changes are not graded: a different level is not good or bad by itself.

Factor ratings for COO

Each factor is rated by where COO stands among the 60 Health Care stocks in our universe.

Rating against the sector

Goodthe top third of these stocks

Averagethe middle third of these stocks

Badthe bottom third of these stocks

"Beats" is the share of those stocks it is ahead of.

Against its own history

The last columns set today's figure against the company's own median of its last five financial years:

▲ Betterbetter than its usual level

▼ Worseworse than its usual level

≈ In linewithin its usual range

For valuation factors Good means cheaper than most of the sector and Better means cheaper than usual for this company, which is not the same as a bargain.

In total: 3 Good · 14 Average · 6 Bad of 23 Growth: 0 · 2 · 1 Profitability: 0 · 3 · 2 Financial strength: 0 · 2 · 2 Valuation: 2 · 3 · 0 Cash flow: 1 · 3 · 0 Efficiency: 0 · 1 · 1

Factor	COO	Rating	Sector median	Own 5-year median	Against own history
Growth
Revenue growth, 3 years a year	+7.3%	Average beats 57%	+5.5%	–	–
Revenue growth, last year	+5.1%	Average beats 34%	+7.1%	+8.6%	▼ Worse
EPS growth, 3 years a year	−1.2%	Bad beats 29%	+5.0%	–	–
Profitability
Gross margin	65.9%	Average beats 55%	65.0%	65.6%	≈ In line
Operating margin	12.8%	Average beats 39%	16.4%	16.7%	▼ Worse
Net margin	13.5%	Average beats 54%	11.1%	10.1%	▲ Better
Return on invested capital	4.3%	Bad beats 14%	12.2%	–	–
Return on equity	6.8%	Bad beats 24%	13.7%	4.9%	≈ In line
Financial strength
Net debt / EBITDA	3.2x	Bad beats 26%	2.0x	2.3x	▼ Worse
Interest cover	6.1x	Average beats 35%	9.4x	6.8x	≈ In line
Current ratio	1.22	Bad beats 28%	1.52	1.89	▼ Worse
Piotroski F-score	6 / 9	Average beats 43%	6 / 9	–	–
Valuation
P/E ratio	20.8x	Good beats 76%	28.2x	45.0x	▲ Better
Price / book	1.4x	Good beats 99%	3.6x	2.0x	▲ Better
Price / sales	2.8x	Average beats 59%	3.7x	4.2x	▲ Better
EV / EBITDA	16.0x	Average beats 59%	17.5x	19.7x	▲ Better
Free cash flow yield	5.7%	Average beats 64%	4.5%	2.2%	▲ Better
Cash flow
Free cash flow margin	16.0%	Average beats 46%	16.3%	10.6%	▲ Better
Cash from operations / net income	1.81	Good beats 70%	1.61	1.81	≈ In line
Free cash flow growth, 3 years a year	−1.3%	Average beats 38%	+4.3%	–	–
Accruals (lower is better)	−3.7%	Average beats 46%	−3.9%	–	–
Efficiency
Inventory turnover	1.6x	Bad beats 15%	2.9x	1.7x	≈ In line
Days sales outstanding	68 days	Average beats 34%	62 days	64 days	≈ In line

These ratings compare companies with each other and describe the past; they are not a forecast, a recommendation or part of the X-Ray Score. A factor is left out when its data is missing or meaningless (for example a P/E on negative earnings). A dash in the history columns means fewer than three usable years.

Fundamentals checklist

● 2 Good · ● 9 Average · ● 5 Bad

Cash quality

Earnings backed by cashAverage

Free-cash-flow yieldAverage

Risk models

Altman Z''Good

Piotroski F-ScoreAverage

Growth

EPS growth (3y)Bad

Free-cash-flow growth (3y)Average

Revenue growth (3y)Average

Growth consistencyGood

Balance sheet

Current ratioBad

Net debt / EBITDABad

Interest coverAverage

Valuation

Fair value vs priceAverage

EBIT / EV yieldAverage

Profitability

Return on invested capitalBad

Operating marginAverage

Gross profitabilityBad

Each check is graded against the company's sector, not a fixed number. Checklist score 42/100.

Financials

	FY21	FY22	FY23	FY24	FY25
Revenue	$2.9B	$3.3B	$3.6B	$3.9B	$4.1B
Operating income	$506M	$508M	$533M	$706M	$683M
Net income	$2.9B	$386M	$294M	$392M	$375M
Operating cash flow	$739M	$692M	$608M	$709M	$796M
Operating margin	17.3%	15.3%	14.8%	18.1%	16.7%
Free cash flow	$524M	$450M	$215M	$288M	$434M
Diluted EPS	$59.16	$1.94	$1.48	$1.96	$1.87

Fiscal years, from SEC filings.

Technical summary

Daily

Bearish

6 bullish · 1 neutral · 9 bearish

Weekly

Strongly bearish

2 bullish · 1 neutral · 9 bearish

Monthly

Strongly bearish

0 bullish · 1 neutral · 7 bearish

Moving averages (daily)

SMA 10	57.95	Bullish
EMA 10	58.68	Bullish
SMA 20	57.01	Bullish
EMA 20	58.09	Bullish
SMA 50	61.92	Bearish
EMA 50	60.78	Bullish
SMA 100	66.24	Bearish
EMA 100	64.10	Bearish
SMA 200	69.46	Bearish
EMA 200	67.80	Bearish

Oscillators (daily)

RSI (14)	61.11	Neutral
MACD (12, 26)	-0.05	Bearish
Momentum (12)	11.80	Bullish
Stochastic %K (14)	93.46	Bearish
Williams %R (14)	-6.54	Bearish
CCI (20)	192.1	Bearish

Pivot points (classic, last session)

59.26

59.86

60.54

Pivot

61.14

61.81

62.41

63.08

Signals describe what the chart is doing, not what to do. Moving averages: price above the average is bullish. Oscillators use the usual thresholds (RSI 30/70, Stochastic 20/80, CCI ±100, Williams %R −80/−20; MACD and momentum above zero are bullish). Weekly and monthly views use closing prices only.

Dividends

Paid, last 12 months

0.00 USD

Yield on today's price

–

Frequency

None in the last year

Next ex-dividend date

Not announced

Ex-dividend date	Amount per share
26 Jul 2023	0.0300
20 Jan 2023	0.0300
26 Jul 2022	0.0300
20 Jan 2022	0.0300
26 Jul 2021	0.0300
21 Jan 2021	0.0300
22 Jul 2020	0.0300
22 Jan 2020	0.0300
22 Jul 2019	0.0300
18 Jan 2019	0.0300

Ex-dividend dates and amounts from EODHD. Shown as declared, before tax.

ETFs that hold COO

ETF	Share of the fund
DFAT DFA Investment Dimensions Group Inc.	0.37%
CGMM Capital Group U.S. Small and Mid Cap	0.36%
FMDE Fidelity Enhanced Mid Cap	0.36%
VBR Vanguard Small-Cap Value	0.30%
XLV Health Care Select Sector SPDR	0.24%
IYH iShares U.S. Healthcare	0.23%
SCHM Schwab U.S. Mid-Cap	0.22%
RSP Invesco S&P 500 Equal Weight	0.21%

The eight funds with the largest weight in COO among the ETFs we cover, from each fund's latest SEC Form N-PORT (quarter-end positions, so they can be months old). All ETFs.